title: Synergistic Interactions of MmpL3 Inhibitors with Antitubercular CompoundsIn Vitro.
abstract: A number of inhibitors of the essentialMycobacterium tuberculosismycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and β-lactams.
authors.affiliation: Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.affiliation: Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
authors.forename: Andrea
authors.initials: A
authors.lastname: Sanchez-Hidalgo
authors.affiliation: Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
authors.forename: Victoria
authors.initials: V
authors.lastname: Jones
authors.affiliation: Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
authors.forename: Vinicius Calado Nogueira
authors.initials: VC
authors.lastname: de Moura
authors.affiliation: Creighton University, School of Pharmacy & Health Professions, Department of Pharmacy Sciences, Omaha, Nebraska, USA.
authors.forename: E Jeffrey
authors.initials: EJ
authors.lastname: North
authors.affiliation: Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA Mary.Jackson@colostate.edu.
authors.forename: Mary
authors.initials: M
authors.lastname: Jackson
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D002991:Clofazimine / Q000494:pharmacology; D064687:Diarylquinolines / Q000494:pharmacology; D004357:Drug Synergism; D026901:Membrane Transport Proteins / Q000378:metabolism*; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000378:metabolism; D009171:Mycolic Acids / Q000378:metabolism; D012293:Rifampin / Q000494:pharmacology; D047090:beta-Lactams / Q000494:pharmacology
chemical_list: D000995:Antitubercular Agents; D064687:Diarylquinolines; D026901:Membrane Transport Proteins; D009171:Mycolic Acids; D047090:beta-Lactams; C493870:bedaquiline; D002991:Clofazimine; D012293:Rifampin
keywords: MmpL3; Mycobacterium; Mycobacterium tuberculosis; drug synergism; mycolic acids; tuberculosis